Could an early measles vaccine slash child deaths? trial tests the idea
NCT ID NCT01644721
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether giving an extra measles vaccine at 4 months, in addition to the standard shot at 9 months, reduces deaths in children up to age 3. Over 3,700 children in Burkina Faso and Guinea-Bissau took part. Researchers tracked survival, hospital visits, and growth to see if the early vaccine provides extra protection beyond preventing measles.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Edmonston-Zagreb measles vaccine
- What this could lead to
- If successful, this could show that giving an early measles vaccine saves more children's lives, leading to updated vaccination schedules in high-risk areas.
- What could go wrong
- This is a completed trial, but results may not apply to other regions or populations. The effect on mortality may be smaller than hoped or influenced by other factors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEASLES VACCINE are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bandim Health Project
Bissau, Guinea-Bissau
More trials for these conditions
Other studies related to the condition(s) this trial covers.